|
|
Article: New Formulation of Allergan's ALPHAGAN(R) P Receives U.S. FDA Approval.
- Article from:
- Business Wire
- Article date:
- August 19, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market ALPHAGAN(R) P (brimonidine tartrate ophthalmic solution) 0.1%, indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
The new product is an optimized formulation of ALPHAGAN(R) (brimonidine tartrate ophthalmic solution) 0.2%, and was developed to further minimize drug exposure while maintaining the drug's favorable efficacy profile. This FDA approval is the latest advance in the ALPHAGAN(R) Franchise, which includes ALPHAGAN(R) P 0.15%, and currently reflects ...